[Clinical features and prognosis of mucosa-associated lymphoid tissue lymphoma].
OBJECTIVE
To explore the clinical features and treatments of mucosa-associated lymphoid tissue (MALT) lymphoma.


METHODS
The clinical data of 80 MALT lymphoma patients treated from September 2000 to November 2012 were retrospectively analyzed.


RESULTS
Among them, 32 (40.0%) had gastric MALT lymphoma and 48(60.0%) non-gastric MALT lymphoma. Gastric lymphoma associated anemia accounted for 50.0% (16/32) (25.0% (12/48) in non-gastric group, P = 0.022). In non-gastric group, stage III-IV diseases accounted for 35.4% (17/48) (12.5% (4/32) in gastric group, P = 0.022). During a median follow-up of 30 months, the 5-year overall survival (OS) rate was 90.0% and 5-year progression-free survival (PFS) rate 67.0%. For the non-gastric group, surgery plus chemotherapy group was superior in PFS to surgery alone group (the 3-year PFS rate 83.0% and 33.0%; median PFS 43.4 months and 20.3 months) (P = 0.040). Five-year OS in patients on first-line rituximab and chemotherapy without rituximab were 100.0% and 86.0% respectively (P = 0.106). Short-term response (OR = 0.258, P = 0.020) and low albumin (OR = 3.967, P = 0.009) were independent factor for PFS.


CONCLUSIONS
Non-gastric MALT lymphoma is easily disseminated. Systemic treatment may be considered for advanced non-gastric MALT lymphoma. Surgery often leaves residual lesions for gastric MALT lymphoma.
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Le
L
Tian
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Chen
C
Zhang
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Weiping
W
Liu
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Xiaopei
X
Wang
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Wen
W
Zheng
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Yan
Y
Xie
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Ningjing
N
Lin
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Zhitao
Z
Ying
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Lingyan
L
Ping
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Lijuan
L
Deng
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Yuqin
Y
Song
Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China. Email: zj@bjcancer.org.
Jun
J
Zhu
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D055815:Young Adult